Literature DB >> 1456588

Control of tuberculosis in the United States. American Thoracic Society.

.   

Abstract

TB continues to be a major public health problem in many areas of the United States. Elimination of this disease will require coordinated efforts of public health agencies, voluntary health associations, health-care providers, and community groups. TB controls is comprised of a variety of activities. Identification and treatment of patients with clinically active disease should be the highest priority for all TB control programs. Identification and preventive treatment of infected contacts and persons with tuberculous infection at greatest risk for developing disease (eg, HIV-infected, young children) should also receive high priority. Attention should then be given to identifying other high-risk groups and administering preventive therapy to those infected. While TB control occurs in many different settings, the health department TB control program plays a pivotal role in providing clinical services, and performing contact investigations, tuberculin-testing and prevention activities, surveillance, and evaluation of the community's overall progress in TB elimination. Health departments should receive strong and continuing support from medical care providers, voluntary health organizations, and community groups if TB elimination is to be achieved.

Entities:  

Mesh:

Year:  1992        PMID: 1456588     DOI: 10.1164/ajrccm/146.6.1623

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

1.  Comparison of the ESP and BACTEC systems for testing susceptibilities of Mycobacterium tuberculosis complex isolates to pyrazinamide.

Authors:  Vincent J LaBombardi
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  Tuberculosis contact investigation policies, practices, and challenges in 11 U.S. communities.

Authors:  Maureen Wilce; Robin Shrestha-Kuwahara; Zachary Taylor; Noreen Qualls; Suzanne Marks
Journal:  J Public Health Manag Pract       Date:  2002-11

4.  Standardizing contact investigation protocols.

Authors:  L B Gerald; F Bruce; C M Brooks; N Brook; M E Kimerling; R A Windsor; W C Bailey
Journal:  Int J Tuberc Lung Dis       Date:  2003-12       Impact factor: 2.373

5.  Evaluation and follow-up of infectious tuberculosis at the University of Ottawa.

Authors:  Z A Memish; R Hickey; I Gemmill
Journal:  Can J Infect Dis       Date:  1995-09

Review 6.  Dormancy of Mycobacterium tuberculosis and latency of disease.

Authors:  L G Wayne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

7.  Molecular fingerprinting of Mycobacterium tuberculosis and risk factors for tuberculosis transmission in Paris, France, and surrounding area.

Authors:  M C Gutiérrez; V Vincent; D Aubert; J Bizet; O Gaillot; L Lebrun; C Le Pendeven; M P Le Pennec; D Mathieu; C Offredo; B Pangon; C Pierre-Audigier
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

8.  Identifying the sources of tuberculosis in young children: a multistate investigation.

Authors:  Sumi J Sun; Diane E Bennett; Jennifer Flood; Ann M Loeffler; Steve Kammerer; Barbara A Ellis
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

9.  Eliminating tuberculosis one neighborhood at a time.

Authors:  J Peter Cegielski; David E Griffith; Paul K McGaha; Melanie Wolfgang; Celia B Robinson; Patricia A Clark; Willis L Hassell; Valerie A Robison; Kerfoot P Walker; Charles Wallace
Journal:  Am J Public Health       Date:  2012-10-18       Impact factor: 9.308

10.  Rethinking the socioeconomics and geography of tuberculosis among foreign-born residents of New Jersey, 1994-1999.

Authors:  Amy L Davidow; Bonita T Mangura; Eileen C Napolitano; Lee B Reichman
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.